Corium International (NASDAQ: CORI) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Corium International to related companies based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, risk and institutional ownership.
Volatility & Risk
Corium International has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Corium International’s competitors have a beta of 37.20, indicating that their average stock price is 3,620% more volatile than the S&P 500.
This is a summary of current ratings for Corium International and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Corium International Competitors||884||3841||6817||181||2.54|
Corium International presently has a consensus target price of $13.50, indicating a potential upside of 30.94%. As a group, “Pharmaceuticals” companies have a potential upside of 18.74%. Given Corium International’s stronger consensus rating and higher possible upside, equities analysts clearly believe Corium International is more favorable than its competitors.
This table compares Corium International and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Corium International Competitors||-2,435.14%||-66.75%||-8.28%|
Valuation & Earnings
This table compares Corium International and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Corium International||$31.86 million||-$47.79 million||-6.17|
|Corium International Competitors||$8.17 billion||$1.09 billion||129.80|
Corium International’s competitors have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
89.4% of Corium International shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are held by institutional investors. 46.5% of Corium International shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Corium International competitors beat Corium International on 7 of the 13 factors compared.
Corium International Company Profile
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.